Achieve Life Sciences (ACHV) vs IDEXX Laboratories (IDXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Achieve Life Sciences (ACHV) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 108.4% versus a loss of 18.5%. Over five years, ACHV leads with a -10.7% price change compared with -19.2% for IDXX. IDEXX Laboratories is the larger company by market cap ($40.43 billion vs $741.3 million), about 54.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACHV | IDXX |
|---|---|---|
| Share price | $7.19 | $513.14 |
| Market cap | $741.31M | $40.43B |
| 1-day change | -0.69% | +1.28% |
| YTD return | +44.67% | -24.15% |
| 1-year return | +108.41% | -18.54% |
| 5-year return | -10.68% | -19.21% |
| P/E ratio (TTM) | — | 36.06 |
| Forward P/E | — | 30.66 |
| EPS (TTM) | $-1.69 | $14.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $4.30B |
| Revenue growth (YoY) | — | +10.42% |
| Net income (latest FY) | — | $1.06B |
| Gross margin | — | 61.80% |
| Operating margin | — | 31.60% |
| Net margin | — | 24.62% |
| 52-week high | $8.64 | $769.98 |
| 52-week low | $2.62 | $500.61 |
| Distance from 52-week high | -16.78% | -33.36% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +96.80% | +36.67% |
| Average volume | 1.43M | 553.95K |
| Shares outstanding | 103.10M | 78.78M |
| Employees | 28 | 11,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IDEXX Laboratories is about 54.5 times larger than Achieve Life Sciences by market value ($40.43B vs $741.31M).
- ACHV has outperformed IDXX by 126.9 percentage points over the past year.
About Achieve Life Sciences
ACHV stock →Achieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 28 employees
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
ACHV vs IDXX FAQ
Which is bigger, Achieve Life Sciences or IDEXX Laboratories?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.43B compared with $741.31M for Achieve Life Sciences (ACHV).
Which stock has performed better over the past year, ACHV or IDXX?
ACHV returned +108.41% over the past 12 months, compared with -18.54% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Are Achieve Life Sciences and IDEXX Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry within the Health Care sector.